CKDXF
Ceryvyn Therapeutics Limited
Price Chart
Latest Quote
$0.01
+0.00 (+0.00%)
Current Price
| Previous Close | $0.01 |
| Open | $0.29 |
| Day High | $0.29 |
| Day Low | $0.29 |
| Volume | 130 |
Stock Information
Note: Financial values converted from AUD to USD
| Shares Outstanding | 1.37B |
| Cash Equivalents | $21.12M |
| Revenue | $704 |
| Net Income | $232.51M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $14.64M |
| P/E Ratio | 0.06 |
| EPS (TTM) | $0.17 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-15.38M |
| Sales | $704 |
| Income | $232.51M |
| Book/sh | $0.02 |
| Cash/sh | $0.02 |
Financial Ratios
| Quick Ratio | 13.43 |
| Current Ratio | 13.78 |
Returns & Margins
| ROA | -12.59% |
| Gross Margin | 100.00% |
| Operating Margin | -1194700.00% |
| Profit Margin | 33044500.00% |
Ownership
| Insider Ownership | 35.43% |
| Institutional Ownership | 4.30% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/S | 14637.37 |
| P/B | 0.69 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.01 |
| SMA50 | $0.01 |
| SMA200 | $0.22 |
| RSI | 100.00 |
| ATR | 0.0001 |
| Shares Float | 772.13M |
| Volatility | 1.48 |
Performance History
| Week | +0.00% |
| Month | +7.00% |
| Quarter | +7.00% |
| 6 Months | -97.57% |
| YTD | -97.57% |
| Year | -97.57% |
| 3 Years | -97.45% |
| 5 Years | -99.02% |
| 10 Years | -97.98% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-29 | $0.01 | 0 |
| 2026-10-28 | $0.01 | 0 |
| 2026-10-27 | $0.01 | 0 |
| 2026-10-26 | $0.01 | 0 |
| 2026-10-23 | $0.01 | 0 |
| 2026-10-22 | $0.01 | 0 |
| 2026-10-21 | $0.01 | 0 |
| 2026-10-20 | $0.01 | 5,455 |
| 2026-10-19 | $0.01 | 0 |
| 2026-10-16 | $0.01 | 0 |
| 2026-10-15 | $0.01 | 0 |
| 2026-10-14 | $0.01 | 0 |
| 2026-10-13 | $0.01 | 0 |
| 2026-10-12 | $0.01 | 0 |
| 2026-10-09 | $0.01 | 0 |
| 2026-10-08 | $0.01 | 0 |
| 2026-10-07 | $0.01 | 0 |
| 2026-10-06 | $0.01 | 0 |
| 2026-10-05 | $0.01 | 0 |
| 2026-10-02 | $0.01 | 0 |
| 2026-10-01 | $0.01 | 0 |
| 2026-09-30 | $0.01 | 0 |
About Ceryvyn Therapeutics Limited
Ceryvyn Therapeutics Limited, a biopharmaceutical company, develops biologic therapy for the rare disease lymphangioleiomyomatosis in Australia. The company offers CYV-101, which is in pre-clinical trial stage, an inhaled therapy intended for delivery directly to the lung. It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was incorporated in 1984 and is headquartered in Hawthorn East, Australia.
đ° Latest News
No news articles available at the moment. Check back later for updates on CKDXF.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $25,000 | $125,000 | $108,000 | $90,683 |
| Operating Revenue | $25,000 | $125,000 | $108,000 | $90,683 |
| Reconciled Cost Of Revenue | - | - | $166,825 | $131,788 |
| Cost Of Revenue | - | - | $166,826 | $131,788 |
| Expenses | ||||
| Interest Expense | $46,457,000 | $30,263,000 | $13,462,000 | $0 |
| Total Expenses | $152,337,000 | $191,967,000 | $150,133,000 | $96,628,646 |
| Other Income Expense | $23,499,000 | $-10,944,000 | $11,813,000 | $-2,814,162 |
| Net Non Operating Interest Income Expense | $-40,925,000 | $-26,868,000 | $-10,235,000 | $235,468 |
| Interest Expense Non Operating | $46,457,000 | $30,263,000 | $13,462,000 | $0 |
| Operating Expense | $152,337,000 | $191,967,000 | $150,133,000 | $96,628,646 |
| Other Operating Expenses | $4,469,000 | $2,584,000 | $8,294,000 | $1,418,204 |
| General And Administrative Expense | $20,537,000 | $12,767,000 | $12,778,000 | $13,594,613 |
| Other Non Operating Income Expenses | - | $387,000 | $12,302,000 | - |
| Rent Expense Supplemental | - | - | - | $21,307 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-162,791,000 | $-220,242,000 | $-142,521,000 | $-92,817,371 |
| Net Interest Income | $-40,925,000 | $-26,868,000 | $-10,235,000 | $235,468 |
| Interest Income | $5,532,000 | $3,395,000 | $3,227,000 | $235,468 |
| Normalized Income | $-185,328,238 | $-209,375,383 | $-142,051,521 | $-90,182,061 |
| Net Income From Continuing And Discontinued Operation | $-162,791,000 | $-220,242,000 | $-142,521,000 | $-92,817,371 |
| Total Operating Income As Reported | $-155,762,000 | $-191,842,000 | $-150,025,000 | $-96,538,132 |
| Net Income Common Stockholders | $-162,791,000 | $-220,242,000 | $-142,521,000 | $-92,817,371 |
| Net Income | $-162,791,000 | $-220,242,000 | $-142,521,000 | $-92,817,371 |
| Net Income Including Noncontrolling Interests | $-162,791,000 | $-220,242,000 | $-142,521,000 | $-92,817,371 |
| Net Income Continuous Operations | $-162,791,000 | $-220,242,000 | $-142,521,000 | $-92,817,371 |
| Pretax Income | $-169,738,000 | $-229,654,000 | $-148,447,000 | $-99,116,657 |
| Special Income Charges | $-3,450,000 | $0 | $0 | $-169 |
| Interest Income Non Operating | $5,532,000 | $3,395,000 | $3,227,000 | $235,468 |
| Operating Income | $-152,312,000 | $-191,842,000 | $-150,025,000 | $-96,537,963 |
| Depreciation Amortization Depletion Income Statement | $91,000 | $103,000 | $101,000 | $78,382 |
| Depreciation And Amortization In Income Statement | $91,000 | $103,000 | $101,000 | $78,382 |
| Depreciation Income Statement | $91,000 | $103,000 | $101,000 | $78,382 |
| Gross Profit | - | - | $-58,420 | $-41,105 |
| Per Share | ||||
| Diluted EPS | $-0.13 | $-0.35 | $-0.28 | $-0.23 |
| Basic EPS | $-0.13 | $-0.35 | $-0.28 | $-0.23 |
| Other | ||||
| Tax Effect Of Unusual Items | $961,762 | $-464,383 | $-19,521 | $-178,852 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-146,689,000 | $-187,957,000 | $-134,395,000 | $-96,224,113 |
| Total Unusual Items | $23,499,000 | $-11,331,000 | $-489,000 | $-2,814,162 |
| Total Unusual Items Excluding Goodwill | $23,499,000 | $-11,331,000 | $-489,000 | $-2,814,162 |
| Reconciled Depreciation | $91,000 | $103,000 | $101,000 | $78,382 |
| EBITDA (Bullshit earnings) | $-123,190,000 | $-199,288,000 | $-134,884,000 | $-99,038,275 |
| EBIT | $-123,281,000 | $-199,391,000 | $-134,985,000 | $-99,116,657 |
| Diluted Average Shares | $1,224,697,353 | $1,091,466,771 | $509,803,546 | $404,906,213 |
| Basic Average Shares | $1,224,697,353 | $1,091,466,771 | $509,803,546 | $404,906,213 |
| Diluted NI Availto Com Stockholders | $-162,791,000 | $-220,242,000 | $-142,521,000 | $-92,817,371 |
| Tax Provision | $-6,947,000 | $-9,412,000 | $-5,926,000 | $-6,299,286 |
| Restructuring And Mergern Acquisition | $3,450,000 | $0 | $0 | - |
| Gain On Sale Of Security | $26,949,000 | $-11,331,000 | $-489,000 | $-2,813,993 |
| Other Taxes | $408,000 | $187,000 | $132,000 | $91,604 |
| Research And Development | $126,832,000 | $176,326,000 | $128,828,000 | $81,445,843 |
| Selling General And Administration | $20,537,000 | $12,767,000 | $12,778,000 | $13,594,613 |
| Other Gand A | $6,226,000 | $2,539,000 | $3,056,000 | $3,368,490 |
| Insurance And Claims | $1,413,000 | $1,669,000 | $2,290,000 | $3,992,816 |
| Salaries And Wages | $12,898,000 | $8,559,000 | $7,432,000 | $6,233,307 |
| Gain On Sale Of Ppe | - | $0 | $0 | $-169 |
| Rent And Landing Fees | - | - | - | $21,307 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-201,069,000 | $-75,810,000 | $-5,853,178 | $47,977,144 |
| Total Assets | $56,799,000 | $188,791,000 | $98,641,319 | $60,046,819 |
| Total Non Current Assets | $0 | $599,000 | $255,021 | $138,377 |
| Non Current Prepaid Assets | $0 | $467,000 | $53,535 | $110,295 |
| Current Assets | $56,799,000 | $188,192,000 | $98,386,298 | $59,908,442 |
| Prepaid Assets | $750,000 | $3,897,000 | $2,634,671 | $8,720,195 |
| Receivables | $7,606,000 | $11,824,000 | $6,562,914 | $6,556,954 |
| Other Receivables | $21,000 | $74,000 | $148,237 | $43,656 |
| Taxes Receivable | $7,488,000 | $11,469,000 | $6,251,824 | $6,456,346 |
| Accrued Interest Receivable | $97,000 | $281,000 | $162,853 | $56,952 |
| Cash Cash Equivalents And Short Term Investments | $48,443,000 | $172,471,000 | $89,188,713 | $44,631,293 |
| Cash And Cash Equivalents | $48,443,000 | $172,471,000 | $89,188,713 | $44,631,293 |
| Cash Equivalents | $34,413,000 | $80,742,000 | $77,121,555 | $32,777,410 |
| Cash Financial | $14,030,000 | $91,729,000 | $12,067,158 | $11,853,883 |
| Accounts Receivable | - | - | - | - |
| Debt | ||||
| Total Debt | $0 | $141,647,000 | $85,841,711 | $0 |
| Long Term Debt And Capital Lease Obligation | - | $141,554,000 | $85,744,226 | $0 |
| Long Term Debt | - | $141,554,000 | $85,660,000 | - |
| Current Debt And Capital Lease Obligation | - | $93,000 | $97,485 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $257,868,000 | $264,601,000 | $104,494,497 | $12,069,675 |
| Total Non Current Liabilities Net Minority Interest | $0 | $200,546,000 | $85,751,858 | $27,974 |
| Current Liabilities | $257,868,000 | $64,055,000 | $18,742,639 | $12,041,701 |
| Other Current Liabilities | $246,993,000 | $24,840,000 | - | - |
| Payables And Accrued Expenses | $9,736,000 | $38,104,000 | $17,891,854 | $11,445,498 |
| Payables | $9,736,000 | $38,104,000 | $17,891,854 | $11,445,498 |
| Total Tax Payable | $0 | $44,000 | $48,873 | $43,334 |
| Accounts Payable | $9,736,000 | $38,060,000 | $17,842,981 | $11,402,164 |
| Other Non Current Liabilities | - | $58,982,000 | $1 | - |
| Equity | ||||
| Common Stock Equity | $-201,069,000 | $-75,810,000 | $-5,853,178 | $47,977,144 |
| Total Equity Gross Minority Interest | $-201,069,000 | $-75,810,000 | $-5,853,178 | $47,977,144 |
| Stockholders Equity | $-201,069,000 | $-75,810,000 | $-5,853,178 | $47,977,144 |
| Gains Losses Not Affecting Retained Earnings | $43,938,000 | $37,809,000 | $32,725,708 | $29,641,280 |
| Retained Earnings | $-742,495,000 | $-579,704,000 | $-359,462,438 | $-216,941,353 |
| Other | ||||
| Ordinary Shares Number | $1,231,817,008 | $1,091,466,771 | $538,046,496 | $405,588,439 |
| Share Issued | $1,231,817,008 | $1,091,466,771 | $538,046,496 | $405,588,439 |
| Tangible Book Value | $-201,069,000 | $-75,810,000 | $-5,853,178 | $47,977,144 |
| Invested Capital | $-201,069,000 | $65,744,000 | $79,806,822 | $47,977,144 |
| Working Capital | $-201,069,000 | $124,137,000 | $79,643,659 | $47,866,741 |
| Capital Lease Obligations | $0 | $93,000 | $181,711 | $0 |
| Total Capitalization | $-201,069,000 | $65,744,000 | $79,806,822 | $47,977,144 |
| Capital Stock | $497,488,000 | $466,085,000 | $320,883,552 | $235,277,217 |
| Common Stock | $497,488,000 | $466,085,000 | $320,883,552 | $235,277,217 |
| Employee Benefits | $0 | $10,000 | $7,631 | $27,974 |
| Current Capital Lease Obligation | $0 | $93,000 | $97,485 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $1,139,000 | $1,018,000 | $753,300 | $596,203 |
| Net PPE | $0 | $132,000 | $201,486 | $28,082 |
| Gross PPE | $0 | $132,000 | $201,486 | $28,082 |
| Long Term Capital Lease Obligation | - | $0 | $84,226 | $0 |
| Other Properties | - | $132,000 | $201,486 | $28,082 |
| Preferred Stock | - | - | - | $0 |
| Long Term Provisions | - | - | - | - |
| Current Provisions | - | - | - | - |
| Investments And Advances | - | - | - | - |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-158,657,000 | $-161,048,000 | $-120,630,000 | $-71,351,862 |
| Operating Activities | ||||
| Cash Flowsfromusedin Operating Activities Direct | $-158,644,000 | $-161,015,000 | $-120,608,000 | $-71,334,952 |
| Classesof Cash Receiptsfrom Operating Activities | $10,598,000 | $6,273,000 | $6,580,000 | $5,519,388 |
| Other Cash Receiptsfrom Operating Activities | $175,000 | $210,000 | $4,000 | $90,683 |
| Operating Cash Flow | - | $-161,015,354 | $-120,608,379 | $-71,334,952 |
| Cash Flow From Continuing Operating Activities | - | $-161,015,354 | $-120,608,379 | $-71,334,952 |
| Operating Gains Losses | - | $-280,283 | $-11,813,023 | $2,814,162 |
| Investing Activities | ||||
| Capital Expenditure | $-13,000 | $-33,000 | $-22,000 | $-16,910 |
| Investing Cash Flow | $-13,000 | $-33,000 | $-22,000 | $-16,910 |
| Cash Flow From Continuing Investing Activities | $-13,000 | $-33,000 | $-22,000 | $-16,910 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $34,809,000 | $158,818,000 | $81,815,000 | $0 |
| Financing Cash Flow | $34,767,000 | $243,729,000 | $167,285,000 | $171,597 |
| Cash Flow From Continuing Financing Activities | $34,767,000 | $243,729,000 | $167,285,000 | $171,597 |
| Net Common Stock Issuance | $34,809,000 | $158,818,000 | $81,815,000 | $0 |
| Common Stock Issuance | $34,809,000 | $158,818,000 | $81,815,000 | $0 |
| Net Other Financing Charges | - | $85,000,000 | $84,500,000 | - |
| Other | ||||
| Repayment Of Debt | $-93,000 | $-89,000 | $-71,000 | $-85,578 |
| End Cash Position | $48,443,000 | $172,471,000 | $89,189,000 | $44,631,293 |
| Beginning Cash Position | $172,471,000 | $89,189,000 | $44,631,000 | $118,193,177 |
| Effect Of Exchange Rate Changes | $-138,000 | $601,000 | $-2,097,000 | $-2,381,619 |
| Changes In Cash | $-123,890,000 | $82,681,000 | $46,655,000 | $-71,180,265 |
| Proceeds From Stock Option Exercised | $51,000 | $0 | $1,041,000 | $257,175 |
| Net Issuance Payments Of Debt | $-93,000 | $-89,000 | $-71,000 | $-85,578 |
| Net Long Term Debt Issuance | $-93,000 | $-89,000 | $-71,000 | $-85,578 |
| Long Term Debt Payments | $-93,000 | $-89,000 | $-71,000 | $-85,578 |
| Net PPE Purchase And Sale | $-13,000 | $-33,000 | $-22,000 | $-16,910 |
| Purchase Of PPE | $-13,000 | $-33,000 | $-22,000 | $-16,910 |
| Taxes Refund Paid Direct | $10,098,000 | $5,926,000 | $6,299,000 | $4,972,898 |
| Interest Received Direct | $5,715,000 | $3,277,000 | $3,122,000 | $216,422 |
| Interest Paid Direct | $-8,000 | $-6,000 | $-17,000 | $-5,920 |
| Classesof Cash Payments | $-174,949,000 | $-170,559,000 | $-130,293,000 | $-77,064,842 |
| Paymentsto Suppliersfor Goodsand Services | $-174,649,000 | $-170,559,000 | $-130,293,000 | $-77,064,842 |
| Receiptsfrom Government Grants | $25,000 | $137,000 | $277,000 | $455,807 |
| Taxes Refund Paid | - | $4,940,507 | $6,299,286 | $4,972,898 |
| Change In Working Capital | - | $17,304,508 | $13,954,720 | $14,664,691 |
| Change In Other Working Capital | - | $266,694 | $136,755 | $115,259 |
| Change In Payables And Accrued Expense | - | $19,502,925 | $7,296,785 | $8,511,607 |
| Change In Payable | - | $19,502,925 | $7,296,785 | $8,511,607 |
| Change In Prepaid Assets | - | $-1,675,274 | $6,142,284 | $5,730,207 |
| Change In Receivables | - | $-789,837 | $378,896 | $307,618 |
| Other Non Cash Items | - | $41,486,577 | $13,462,160 | - |
| Stock Based Compensation | - | $5,084,613 | $5,834,686 | $5,251,572 |
| Deferred Tax | - | $-9,412,196 | $-5,926,350 | $-6,299,286 |
| Deferred Income Tax | - | $-9,412,196 | $-5,926,350 | $-6,299,286 |
| Depreciation Amortization Depletion | - | $103,025 | $101,227 | $78,382 |
| Depreciation And Amortization | - | $103,025 | $101,227 | $78,382 |
| Depreciation | - | $103,025 | $101,227 | $78,382 |
| Pension And Employee Benefit Expense | - | $-387,284 | $-12,302,160 | $0 |
| Net Foreign Currency Exchange Gain Loss | - | $107,001 | $489,137 | $2,813,993 |
| Net Income From Continuing Operations | - | $-220,242,105 | $-142,521,085 | $-92,817,371 |
| Net Investment Purchase And Sale | - | - | - | $0 |
| Sale Of Investment | - | - | - | $0 |
Fetched: 2026-02-02